Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection

Francesco Di Mario, Ali Mahamat Moussa, Lucas Giovanni Cavallaro, Pietro Caruana, Roberta Merli, Simone Bertolini, Veronica Iori, Giulia Martina Cavestro, Nadia Dal Bò, Alberto Pilotto, Angelo Franzé, Gioacchino Leandro

Research output: Contribution to journalArticle

Abstract

Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ± 7.4 vs. 8.6 ± 3.7 μg/l; p <0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGII Δvalue (sPGII variation divided by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalDigestion
Volume70
Issue number3
DOIs
Publication statusPublished - 2004

Keywords

  • H. pylori, eradication therapy
  • Helicobacter pylori
  • Serum pepsinogen II

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection'. Together they form a unique fingerprint.

  • Cite this

    Di Mario, F., Moussa, A. M., Cavallaro, L. G., Caruana, P., Merli, R., Bertolini, S., Iori, V., Cavestro, G. M., Dal Bò, N., Pilotto, A., Franzé, A., & Leandro, G. (2004). Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. Digestion, 70(3), 167-172. https://doi.org/10.1159/000081517